Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica vaccine trial

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 7, 2013, Pages 1399-1406

  Safaeian, Mahboobeh ^a   Kemp, Troy J ^b   Pan, David Yuanji ^b   Porras, Carolina ^c   Rodriguez, Ana Cecilia ^c   Schiffman, Mark ^a   Cortes, Bernal ^c   Katki, Hormuzd ^a   Wacholder, Sholom ^a   Schiller, John T ^a   Gonzalez, Paula ^c,e   Penrose, Kerri ^b   Lowy, Douglas R ^a   Quint, Wim ^d   Van Doorn, Leen Jan ^d   Herrero, Rolando ^c,e   Hildesheim, Allan ^a   Pinto, Ligia A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^d DDL DIAGNOSTIC LABORATORY   (Netherlands)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cross protection; HPV vaccine; Humoral; Immune response; Mechanisms for protection

Indexed keywords

BIOLOGICAL MARKER; HUMAN PAPILLOMAVIRUS L1 ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; WART VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; CASE CONTROL STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; HUMORAL IMMUNITY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS ATTACHMENT; VIRUS NEUTRALIZATION;

CROSS-PROTECTION; HPV VACCINE; HUMORAL; IMMUNE RESPONSE; MECHANISMS FOR PROTECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CASE-CONTROL STUDIES; COSTA RICA; CROSS PROTECTION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 31; HUMANS; IMMUNITY, HUMORAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84880912594     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24340     Document Type: Conference Paper

References (23)

1. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4.
2. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 viruslike- particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1016/S0140-6736(07)60946-5.
3. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199:936-44; PMID:19236277; http://dx.doi.org/10.1086/597309.
4. Herrero R, Wacholder S, Rodríguez AC, Solomon D, González P, Kreimer AR, et al.; Costa Rica Vaccine Trial Group. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011; 1:408-19; PMID:22586631; http://dx.doi.org/10.1158/2159-8290.CD-11-0131.
5. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63; PMID:7745754.
6. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995; 92:11553-7; PMID:8524802; http://dx.doi.org/10.1073/pnas.92.25.11553.
7. Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010; 118(Suppl):S12-7; PMID:20494219; http://dx.doi.org/10.1016/j.ygyno.2010.04.004.
8. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006; 6:231-43; PMID:16498452; http://dx.doi.org/10.1038/nri1783.
9. Roost HP, Bachmann MF, Haag A, Kalinke U, Pliska V, Hengartner H, et al. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc Natl Acad Sci U S A 1995; 92:1257-61; PMID:7877965; http://dx.doi. org/10.1073/pnas.92.5.1257.
10. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3:85ra48; PMID:21632986; http://dx.doi.org/10.1126/scitranslmed.3002336.
11. Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 2012; 19:1075-82; PMID:22593236; http://dx.doi.org/10.1128/CVI.00139-12.
12. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, et al.; HPV-010 Study Group. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7:1359-73; PMID:22048172; http://dx.doi.org/10.4161/hv.7.12.18282.
13. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011; 29:2011-4; PMID:21241731; http://dx.doi.org/10. 1016/j.vaccine. 2011.01.001.
14. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3:109-15; PMID:17611417; http://dx.doi.org/10. 4161/hv.3.4.4058.
15. Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, Soldan K, et al. Neutralization of nonvaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 2011; 29:8585-90; PMID:21939712; http://dx.doi.org/10.1016/j.vaccine.2011.09.021.
16. Herrero R, Hildesheim A, Rodríguez AC, Wacholder S, Bratti C, Solomon D, et al.; Costa Rica Vaccine Trial (CVT) Group. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008; 26:4795-808; PMID:18640170; http://dx.doi.org/10.1016/j.vaccine.2008.07.002.
17. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425-34; PMID:18948732; http://dx.doi.org/10.4161/hv.4.6.6912.
18. Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, et al.; Costa Rica Vaccine Trial (CVT) Group. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008; 26:3608-16; PMID:18541349; http://dx.doi.org/10. 1016/j.vaccine.2008.04.074.
19. Dauner JG, Pan Y, Hildesheim A, Kemp TJ, Porras C, Pinto LA. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes 2012; 26:73-80; PMID:22285687; http://dx.doi.org/10.1016/j.mcp.2012.01.002.
20. Laeyendecker O, Latimore A, Eshleman SH, Summerton J, Oliver AE, Gamiel J, et al. The effect of sample handling on cross sectional HIV incidence testing results. PLoS One 2011; 6:e25899; PMID:22046249; http://dx.doi.org/10.1371/ journal.pone.0025899.
21. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37:2508-17; PMID:10405393.
22. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006; 44:3292-8; PMID:16954263; http://dx.doi.org/10.1128/JCM.00539-06.
23. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30; PMID:3719049; http://dx.doi.org/10.2307/2531248.